These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12605743)

  • 1. [Cost-effectiveness analysis of the use of celecoxib for the treatment of osteoarthritis].
    Moreno A; Vargas E; Soto J; Rejas J
    Gac Sanit; 2003; 17(1):27-36. PubMed ID: 12605743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
    You JH; Lee KK; Chan TY; Lau WH; Chan FK
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic model of long-term use of celecoxib in patients with osteoarthritis.
    Loyd M; Rublee D; Jacobs P
    BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
    Al MJ; Maniadakis N; Grijseels EW; Janssen M
    Value Health; 2008; 11(4):589-99. PubMed ID: 18194404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.
    Schaefer M; DeLattre M; Gao X; Stephens J; Botteman M; Morreale A
    Curr Med Res Opin; 2005 Jan; 21(1):47-60. PubMed ID: 15881475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
    De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
    Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
    Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
    Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
    Spiegel BM; Targownik L; Dulai GS; Gralnek IM
    Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
    Brereton N; Pennington B; Ekelund M; Akehurst R
    J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
    Burke TA; Zabinski RA; Pettitt D; Maniadakis N; Maurath CJ; Goldstein JL
    Pharmacoeconomics; 2001; 19 Suppl 1():33-47. PubMed ID: 11280104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Haglund U; Svarvar P
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():51-6. PubMed ID: 11276803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
    Becker RV; Burke TA; McCoy MA; Trotter JP
    Clin Ther; 2003 Feb; 25(2):647-62. PubMed ID: 12749519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib.
    Pettitt D; Goldstein JL; McGuire A; Schwartz JS; Burke T; Maniadakis N
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():33-42; discussion 57-9. PubMed ID: 11276801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway.
    Svarvar P; Aly A
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():43-50. PubMed ID: 11276802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
    Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice.
    Turajane T; Chaweevanakorn U; Sungkhun P; Larbphiboonpong V; Wongbunnak R
    J Med Assoc Thai; 2012 Oct; 95 Suppl 10():S98-104. PubMed ID: 23451446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC
    Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.